Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Total Non-Current Liabilities: 2015-2024

Historic Total Non-Current Liabilities for Editas Medicine (EDIT) over the last 8 years, with Dec 2024 value amounting to $204.2 million.

  • Editas Medicine's Total Non-Current Liabilities rose 23.52% to $183.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $183.6 million, marking a year-over-year increase of 23.52%. This contributed to the annual value of $204.2 million for FY2024, which is 37.76% up from last year.
  • Latest data reveals that Editas Medicine reported Total Non-Current Liabilities of $204.2 million as of FY2024, which was up 37.76% from $148.3 million recorded in FY2023.
  • Over the past 5 years, Editas Medicine's Total Non-Current Liabilities peaked at $204.2 million during FY2024, and registered a low of $148.3 million during FY2023.
  • Its 2-year average for Total Non-Current Liabilities is $176.2 million, with a median of $176.2 million in 2023.
  • In the last 5 years, Editas Medicine's Total Non-Current Liabilities slumped by 38.52% in 2020 and then surged by 37.76% in 2024.
  • Yearly analysis of 3 years shows Editas Medicine's Total Non-Current Liabilities stood at $151.5 million in 2020, then reached $148.3 million in 2023, then spiked by 37.76% to $204.2 million in 2024.